Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.


Related Content

Cholesterol Drug Approvals May Hinge On Outcomes Studies; FDA Rejects Diabetes-style Tiered Trials
Vascepa Negative Panel Vote Clouds Future For Other Cholesterol Drugs
Panel To Weigh Amarin’s Expanded Vascepa Use Given Clinical Outcome Concerns
The Other Fish In The Sea: AstraZeneca Buys Omthera
As Some New Listings Thrive, IPO Pipeline Burgeons
Abbvie: A Glimpse Of What The New Biopharma Will Look Like
Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa
Amarin Aims Vascepa For The Sweet Spot Of Dyslipidemia
As It Soaks Up Good Trial Results, Amarin Ponders Partners - Or None
Amarin Shuffles Management Again, But Says Omega-3 Trial Results Are Near


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts